Marketers need to dig deeper to facilitate communications that are dynamic enough to reach and engage patients on a more personal, emotional level.
The U.S. FDA approved Ironwood Pharmaceuticals Inc.’s Duzallo as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.
Alkermes plc announced the initiation of its rolling submission of a New Drug Application to the U.S. Food and Drug Administration, seeking marketing approval of ALKS 5461. The once-daily, oral vestigational medicine with a novel mechanism of action is intended for the adjunctive treatment of major depressive disorder MDD).
The Greater Than One Group (GTO) announced that James P. Plattner joined the firm as Global Chief Financial Officer.
Genome BC is investing in a cancer research project that aims to speed up genetic tests of tumors through the development of a robotics system.
The FDA accepted for filing Seattle Genetics’ supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma.
W2O Sentient announced the appointment of respected industry leaders Dominic Viola as Managing Director, Client Services, and Michael Spitz as Practice Leader, Strategy.
Discovery Worldwide announced the appointment of Stephanie Franke as VP, Creative Director. Franke reports directly to TJ Cimfel, Group VP Creative Director.
Takeda Pharmaceutical announced a collaboration to help transform novel Stanford University research into next-generation treatments for diseases.
CEL-SCI received a letter from the U.S. FDA stating that the clinical hold that had been imposed on the company’s Phase 3 cancer study with Multikine was removed.
